Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07115329 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Syndeio Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT07115329 is a Phase 2 study of Major Depressive Disorder that is actively recruiting participants, run by Syndeio Biosciences. The registered enrollment target is 164 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT07115329, a Phase 2 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Syndeio Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel1)? What medical problems are observed in participants who take zelquistinel? Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.
Conditions Studied
Interventions
- DRUG Zelquistinel
Study Locations (20)
California
- Catalina Research Institute, LLC - Montclair
- Excell Research, Inc - Oceanside
- Anderson Clinical Research - Redlands
- Studyops Inc - San Francisco
- Lumos Clinical Research Center - San Jose
- Sunwise Clinical Research - Walnut Creek
Florida
- Clinical Neuroscience Solutions, Inc - Jacksonville
- Premier Clinical Research Institute Inc - Miami
- Aqualane Clinical Research - Naples
- EquiPath Health and Research Tampa Bay, LLC - Riverview
- Neuroscience Research Institute - West Palm Beach
Arizona
- NoesisPharma, LLC - Phoenix
- Del Sol Research Management - Tucson
Maryland
- Sunstone Therapies - Rockville
- Continental Clinical Solutions - Towson
Georgia
- Denali Health Atlanta, LLC - Stone Mountain
Illinois
- EmVenio Research - Chicago
Louisiana
- Tandem Clinical Research - Metairie
Massachusetts
- Vitalix Clinical - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07115329
The ClinicalTrials.gov registry entry for NCT07115329 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (56% lower). The listed sponsor is Syndeio Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Zelquistinel is the first listed.
NCT07115329 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07115329 about?
NCT07115329 is a clinical study titled "A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder". The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l...
What is the current status of trial NCT07115329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2026-01-05. Estimated completion is 2028-06.
What conditions does trial NCT07115329 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT07115329?
The interventions under investigation include: Zelquistinel (DRUG).
Who is sponsoring clinical trial NCT07115329?
This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07115329 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.